A pool of monoclonal antibodies (MAbs) raised against the unknown organism causing the proliferative kidney disease of salmonid fish (PKX) has been used to screen a cDNA expression library constructed from poly (A+) RNA extracted from PKX infected kidney. Four immunopositive lambda ZapII recombinant phages were selected. Sequencing of the cDNAs revealed identical 3' ends. The longest cDNA clone (2652 nucleotides) had an open reading frame (ORF) of 872 amino acids and encoded a protein with a predicted size of 101 kDa (PKX101). Sequence analysis of PKX101 revealed two leucine zipper motifs, a putative transmembrane region and a microbody targeting signal at its C-terminal end. Three cDNA fragments were subcloned in pET-14b expression vector and the ORF verified by an in vitro transcription/translation procedure. Recombinant clones were expressed in Escherichia coli and the antigenicity of fusion proteins was studied by Western blotting using monoclonal antibodies directed against PKX cells and a pool of serum from preimmune or PKX-infected rainbow trout. Western blotting of enriched PKX cell antigen probed with one MAb or with sera from infected trout revealed a single protein with relative mobility of 13 kDa (PKX13). This discrepancy between PKX101 and PKX13 observed in Western blot suggests post-translational modifications of the full-length PKX antigen.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0166-6851(96)02761-2 | DOI Listing |
Anticancer Agents Med Chem
January 2025
Department of Chemistry, Faculty of Sciences, Muğla Sıtkı Koçman University, Turkey.
Objective: Lung cancer is the primary cause of cancer-related deaths globally. Protein kinase B (AKT) protein is associated with many pathways in non-small cell lung cancer (NSCLC), such as proliferation, migration, invasion, and apoptosis. Mushrooms have a long history of being used in traditional medicine to treat various diseases.
View Article and Find Full Text PDFMol Cancer
January 2025
Department of Cell Biology, Physiology, and Immunology, University of Córdoba, CIBER Pathophysiology of Obesity and Nutrition (CIBERobn), Córdoba, 14004, Spain.
Background: Hepatocellular carcinoma (HCC) genetic/transcriptomic signatures have been widely described. However, its proteomic characterization is incomplete. We performed non-targeted quantitative proteomics of HCC samples and explored its clinical, functional, and molecular consequences.
View Article and Find Full Text PDFNat Commun
January 2025
Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.
Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) can mediate tumor regression, including complete and durable responses, in a range of solid cancers, most notably in melanoma. However, its wider application and efficacy has been restricted by the limited accessibility, proliferative capacity and effector function of tumor-specific TIL. Here, we develop a platform for the efficient identification of tumor-specific TCR genes from diagnostic tumor biopsies, including core-needle biopsies frozen in a non-viable format, to enable engineered T cell therapy.
View Article and Find Full Text PDFPLoS One
January 2025
School of Life Science, Inner Mongolia University, Hohhot, PR China.
Ovarian tissue cryopreservation addresses critical challenges in fertility preservation for prepubertal female cancer patients, such as the lack of viable eggs and hormonal deficiencies. However, mitigating follicle and granulosa cell damage during freeze-thaw cycles remains an urgent issue. Luteinizing hormone (LH), upon binding to luteinizing hormone receptors (LHR) on granulosa cells, enhances estrogen synthesis and secretion, contributing to the growth of granulosa cells and follicles.
View Article and Find Full Text PDFImmunol Res
January 2025
Department of Immunology, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Türkiye.
B-cell acute lymphoblastic leukemia (B-ALL) is the most common form of cancer diagnosed in children. While the majority of patients survive with conventional treatment, chemotherapeutic agents have adverse effects and the potential for relapse persists even after full recovery. Given their pivotal function in anti-cancer immunity, there has been a surge in research exploring the potential of natural killer (NK) cells in immunotherapy, which has emerged as a promising avenue for treating leukemia.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!